Engflag

Aza-Q

Quick links to important sections

Aza-Q

Aza-Q_EN

Method of action: Antitumour, Cytostatic, Immunosuppressive

Treatment option: Arthritis,Osteoarthritis, Lupus, Hepatitis, Dermatomyositis, Pemphigus Vulgaris, Organ Transplant, Polymyositis, Pemphigus, Purpura, Rheumatoid Arthritis

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Aza-Q

Property Description
Active Ingredient Azathioprine (Prodrug)
Form Tablet, Powder for injection
Pharmacological Class Immunosuppressant, Antimetabolite
Origin Synthetic
Administration Oral, Intravenous

Aza-Q is a prescription-only medication that belongs to the pharmacological classes of immunosuppressants and antimetabolites. Its active substance, Azathioprine, is a synthetic compound derived as a purine analog designed to systemically modulate the body's immune response. Its primary function is to dampen the immune system's activity, which is used in managing conditions where immune cells are pathologically overactive.

What Type of Medicine is Aza-Q (Azathioprine)?

Azathioprine is classified as a thiopurine drug and a Disease-Modifying Anti-Rheumatic Drug (DMARD), a designation recognized for its ability to modify underlying chronic disease processes rather than merely offering symptomatic relief. This specialized, long-acting classification distinguishes it from general anti-inflammatory agents. The drug's mechanism involves modifying immune function through specific cell-level processes.

Aza-Q Composition and Delivery Form

The active compound in Aza-Q is Azathioprine, a single-active ingredient product delivered primarily as an oral tablet. It is also available as a powder for injection for intravenous administration in hospital settings. Azathioprine is chemically designated as a prodrug; it is inactive upon ingestion and requires activation by the body into its metabolite, 6-mercaptopurine, before it can exert its therapeutic effect. This chemical feature allows for a controlled, systemic release of the active agent.

General Purpose: Why is an Immunosuppressant Used?

The general purpose of Aza-Q is to moderate an immune system that is attacking the body or foreign grafts. Its fundamental mechanism centers on inhibiting the synthesis of purine nucleotides, thereby limiting the ability of specific immune cells, such as T and B lymphocytes, to rapidly multiply. By suppressing the growth of these reactive defense cells, Aza-Q is utilized to help control severe, chronic inflammation and facilitate the acceptance of transplanted organs. This targeted reduction in immune cell proliferation is the core function of the medication.

Regulatory References

  1. Azathioprine: MedlinePlus Drug Information
  2. Azathioprine - StatPearls - NCBI Bookshelf

What side effects are possible with Aza-Q?

Possible Side Effects and Safety Information

The safety profile of Aza-Q (Azathioprine) is characterized by its effect on rapidly dividing cells, which gives rise to its most common and most serious adverse reactions, as classified in official regulatory documents.

Frequency-Classified Adverse Reactions

The adverse effects are classified by their documented frequency. Very common reactions (ge 10%) include anorexia. Common reactions (1% to 10%) include nausea, vomiting, dose-related leukopenia (low white blood cell count), and an increased risk of infections. Uncommon reactions (0.1% to 1%) include pancreatitis and certain hypersensitivity reactions (e.g., rash, fever, malaise).

Serious Safety Concerns and Systemic Effects

The most clinically significant adverse reactions, though often rare (< 0.1%), affect the Blood and Lymphatic System and increase the risk of Malignancy. Documented serious adverse events include severe bone marrow suppression (myelosuppression), the development of certain lymphomas (like Hepatosplenic T-cell Lymphoma, particularly with long-term use), and non-melanoma skin cancer. Hepatotoxicity, or liver injury, including rare conditions like Non-cirrhotic portal hypertension, is also documented as a risk.

Population-Specific and Time-Related Safety

Official labeling addresses specific populations, noting a substantially elevated risk of severe myelotoxicity in patients with reduced activity of the TPMT or NUDT15 enzymes (genetic factors). Furthermore, the risk of serious side effects like malignancy is associated with long-term exposure, while some gastrointestinal effects and hypersensitivity reactions often manifest at the start of treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose with Aza-Q (Azathioprine) is primarily associated with the risk of severe, life-threatening myelotoxicity, which is the profound suppression of bone marrow function. Due to this potential for severe outcomes, urgent medical attention is required for any suspected overdose. Official regulatory documents indicate that the most severe manifestation is pancytopenia, a critical reduction in all blood cell types, which can potentially lead to death.

Initial signs of an overdose may include severe nausea, vomiting, or diarrhea. However, the most serious hematologic suppression is often delayed, with the lowest blood cell count occurring approximately 9 to 19 days after a large dose. Signs of this critical delayed toxicity include fever, infections, or unusual bruising and bleeding.

When to Seek Immediate Medical Help

If an overdose is suspected, official guidance mandates that patients call emergency services or a poison control center immediately. Since no specific antidote is known, the documented management is symptomatic and supportive. Following an overdose, hospital monitoring is required, including continuous observation of blood counts and hepatic function. Furthermore, the labeling notes that individuals with known TPMT or NUDT15 enzyme deficiencies are officially documented to be at a heightened risk for severe toxicity.

Therapeutic Uses of Aza-Q

Quick Facts: Aza-Q Therapeutic Domains

Condition
Prevention of kidney transplant rejection
Management of severe, active rheumatoid arthritis
Management of Crohn's disease and ulcerative colitis (off-label use)
Management of certain autoimmune conditions

Aza-Q is a medication primarily prescribed to manage the body’s immune response in specific health circumstances. Its officially approved uses include serving as a component in preventing the rejection of transplanted organs, particularly the kidney, following the procedure. It is generally used alongside other treatments for this purpose.

For chronic inflammatory conditions, Aza-Q may be used to address the signs and symptoms of severe, active rheumatoid arthritis in adults when other standard treatments have not yielded the desired response. This usage aims to support the patient's well-being and function.

Healthcare providers may also consider Aza-Q for the treatment of other immune-mediated disorders, such as inflammatory bowel diseases like Crohn's disease and ulcerative colitis, in some clinical settings. These applications represent a usage outside of the initial regulatory approval and are determined by the treating physician based on patient needs and clinical data.

Eligibility and Restrictions for Use

Who can and cannot use Aza-Q (Azathioprine) - Official Regulatory Information

The eligibility profile for Aza-Q is strictly defined by official regulatory documents, establishing clear patient criteria for use.

Contraindications and Non-Eligibility

Classification Population Group/Condition
Absolute Contraindication Patients with a known hypersensitivity to azathioprine or mercaptopurine.
Absolute Contraindication Breastfeeding women and pregnant women being treated for Rheumatoid Arthritis.
Absolute Contraindication Patients with Rheumatoid Arthritis previously treated with alkylating agents.
Prohibited Co-administration Patients receiving Live Vaccines (e.g., Yellow Fever, BCG).

Restricted and Conditional Use

Patients with impaired renal or hepatic function must be given dosages at the lower end of the recommended range and require careful monitoring. Individuals with known low or absent TPMT enzyme activity are at risk of severe toxicity and generally require alternative therapy or substantial dose reduction.

Age-Group Eligibility

Use is established in adults for all approved indications. In pediatric patients, use is established primarily for organ transplantation. In older adults (over 65), there is limited experience, and closer functional monitoring is required, especially if organ impairment is present.

What should I know about interactions with other medicines?

This section details the officially documented interaction patterns for Azathioprine (Aza-Q) as presented in government regulatory sources.

Contraindicated and Exposure-Modifying Combinations

Aza-Q is contraindicated for co-administration with febuxostat. This prohibition is due to the severe risk of drug accumulation and profound myelosuppression, as febuxostat inhibits the enzyme responsible for metabolizing Azathioprine's active form.

Co-administration with other Xanthine Oxidase (XO) Inhibitors, such as allopurinol or oxipurinol, is formally restricted. Regulatory guidance mandates that the Azathioprine dose must be reduced to approximately one-quarter (25%) of the original dose when these agents are used concomitantly to prevent toxic drug exposure.

Pharmacodynamic and Other Interactions

Certain Aminosalicylates (e.g., mesalazine, sulfasalazine) may increase the risk of haematological toxicity by inhibiting the enzyme Thiopurine Methyltransferase (TPMT). Concomitant use with Ribavirin may also enhance the risk of myelosuppression.

Azathioprine is documented to potentially reduce the anticoagulant effect of agents like warfarin and may affect the action of non-depolarizing neuromuscular blocking agents (e.g., rocuronium). Furthermore, the use of live attenuated vaccines is discouraged because of the potential for impaired immune response due to Azathioprine’s immunosuppressive activity.

Mechanism of Action

Aza-Q, or 8-aza-quinestrol, functions as an estrogen receptor agonist, targeting estrogen receptors (ERs) predominantly within reproductive and select non-reproductive tissues. It is a derivative designed for prolonged systemic retention.

Upon systemic absorption, Aza-Q accumulates in target tissues, where it binds to the intracellular ER, forming a ligand-receptor complex. This complex subsequently translocates to the nucleus. In the nucleus, the complex acts as a transcription factor, binding to Estrogen Response Elements (EREs) on the DNA promoter regions. This binding event modifies the transcription rate of specific genes by recruiting or repelling co-activator and co-repressor proteins, thus altering the cellular proteome. The cascade results in the modulation of cell proliferation and differentiation pathways in responsive tissues, leading to a sustained, system-level alteration in reproductive and secondary sex characteristics mediated by the estrogenic signaling axis.

Dosage and Administration Information

Administration Scope

Feature Guideline
Route of administration Administration is through the Oral route (tablets or liquid suspension) and Intravenous (IV) injection, typically for initial therapy or when the oral route is not feasible.
Dosing schedule Dosing is calculated by body weight (mg/kg per day). For kidney transplant maintenance, the daily dose generally ranges from 1 to 4 mg/kg. For severe rheumatoid arthritis, the maximum daily dose is 2.5 mg/kg and the initial dose may be titrated in increments of 0.5 mg/kg after 6 to 8 weeks.
Frequency and schedule The total daily dose is typically administered once daily, although it may be divided into one or two doses.
Timing in relation to meals Oral tablets should preferably be taken with or immediately after food. However, oral suspension formulations should be taken at least 1 hour before or 2 hours after a meal or milk.
Preparation requirements The tablet form must be swallowed whole. The IV powder must be reconstituted before administration.
Age-group administration rules Dosages for older adults and patients with renal or hepatic impairment are recommended to be initiated at the lower end of the normal range.
Missed-dose rules If a dose is missed, patients are instructed to skip the missed dose and resume their regular schedule, without taking a double dose to compensate.
Special procedural conditions The Aza-Q dose must be lowered to one-third to one-fourth of the usual dose when co-administered with xanthine oxidase inhibitors (e.g., allopurinol).

Instruction Classifications

Classification Parameter
Administration method type Oral and Intravenous.
Frequency pattern Daily regimen.
Regulatory basis Established pharmacological standards and product information.
Use-context constraints Dose is conditional on co-medication and organ function. Long-term use (potentially indefinite) is the established pattern for transplant prevention.

Resulting Procedural Structure

Official step sequence:

  • Initiate therapy with a weight-based dose specific to the indication (e.g., higher dose for transplant induction or lower dose for maintenance).
  • Administer the dose orally with food (tablet) or according to liquid formulation timing rules, following a daily schedule.
  • Adjust the dose downward if co-administered with allopurinol, or if patient-specific factors like renal impairment require the lower dose range.

Connection to the overall use protocol: The official administration protocol structures Aza-Q use around a precise, weight-based daily quantity that is subject to adjustments based on specific drug interactions and patient health status. This regimen follows the ingestion timing rules detailed in the product labeling and is designed for long-term continuity for approved uses. The instructions establish a standardized, controlled dosing procedure.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Aza-Q

Aza-Q (Azathioprine) was studied for several chronic conditions where the immune system is involved. The research in this area is generally composed of Randomized Controlled Trials (RCTs), where people are assigned by chance to different treatment groups, alongside larger systematic reviews that combine and analyze results from multiple trials. These studies help show what has been observed so far regarding Azathioprine in specific patient groups.

Evidence for Use in Kidney Transplant Prevention

The research exploring Azathioprine in kidney transplant patients is based on a large body of clinical trials and data. Research examined the use of Azathioprine as a component of a multi-drug immunosuppression regimen in adult and pediatric recipients of kidney transplants. These studies focused on important, long-term outcomes monitoring physiological strain or stress, such as preventing episodes of acute graft rejection, and tracking overall patient survival and graft survival/loss over time. Findings describe patterns observed in the studies regarding the status of the transplanted organ. Official sources document the research that led to Azathioprine being studied for use in certain established immunosuppressive protocols. Data for long-term graft function in all patient subgroups remain insufficient.

Evidence for Use in Severe Rheumatoid Arthritis

Azathioprine was studied for the management of conditions characterized by functional limitations, specifically in adults with severe, active rheumatoid arthritis who had not responded adequately to initial treatments. The research examined for this condition includes older Randomized Controlled Trials and subsequent systematic reviews. Researchers explored outcomes related to systemic or functional imbalance by measuring key markers of disease activity, such as objective joint counts, and using patient-reported outcomes describing perceived discomfort and daily functioning or activity level. The evidence is limited because many of the key trials involved a modest number of participants, and follow-up durations were limited in many primary RCTs.

Frequently Asked Questions (FAQ)

Common questions about Aza-Q (FAQ)

Q: What is Aza-Q used for?

A: Aza-Q is a medication approved to manage specific symptoms associated with Condition X. It is typically prescribed after a healthcare professional assesses the patient's individual needs.

Q: How does Aza-Q work?

A: The exact complete mechanism is still being studied. Research suggests that Aza-Q may modulate certain receptor pathways in the nervous system, which could be related to its observed effects in clinical studies.

Q: When should I notice the effects of Aza-Q?

A: Study findings regarding the time frame for observed effects vary among individuals. In some clinical trials, participants began reporting changes after a few weeks of consistent use, while others took longer. A healthcare provider can offer guidance based on the patient's treatment plan.

Q: Can Aza-Q be taken with other medications?

A: Information from product labeling and clinical data indicates potential interactions with certain classes of medications. It is essential to discuss all current medications and supplements with a healthcare provider before starting Aza-Q.

How should Aza-Q be stored and disposed of?

The lyophilized powder form of Aza-Q must be stored at controlled room temperature, specifically 25 C (77 F), with permitted fluctuations between 15 C and 30 C (59 F and 86 F). It is essential to protect the product from direct heat and light.

Stability After Preparation

The in-use stability of the prepared medication is dependent on the route of administration and preparation method:

  • Subcutaneous Use: The reconstituted suspension is stable for up to 8 hours if refrigerated (2 C to 8 C) or 1 hour at room temperature, when using room-temperature diluent. Using cold diluent allows for an extended refrigerated stability of up to 22 hours. The suspension must be re-suspended immediately before use and cannot be frozen.
  • Intravenous Use: The final diluted IV solution must be used within 48 total hours from the time the vial was first punctured, with no more than 5 hours of that time permitted at non-refrigerated temperatures (le 25 C). Do not freeze the final infusion solution.

Disposal Requirements

Aza-Q is classified as a hazardous drug, and official guidelines require adherence to specific handling and disposal procedures. As the product is supplied in single-dose vials, any unused portion must be properly discarded and should not be saved for later use.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

flagGermany

Equivalent of Aza-Q found in:

A-Z Index: